Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.7MCash on Hand
9.1mo Cash Runway
Follow GANX by emailGet an email when GANX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GANX, unsubscribe in one click. Privacy
📣 What GANX Says Is Next
Q1 2027 · “Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q1 2027.”
Company press release, Nov 10, 2026 · SEC filing
Q1 2027 · “Initiation of rexaceract Phase 2 clinical trial expected during Q1 2027 following a comprehensive redesign and submission of new Phase 2 protocol.”
Company press release, Nov 10, 2026 · SEC filing
coming weeks · “The Company expects to submit a new Phase 2 study protocol to the U.S. Food and Drug Administration (the “FDA”) in the coming weeks, informed by insights provided by the Phase 1b study results and recent discussion with potential partners, and initiate the Phase 2 clinical trial of rexaceract in people with Parkinson’s disease in the first quarter of 2027.”
Company press release, Oct 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Reported Q3 2026 R&D expenses of $1.4 million versus $2.8 million a year earlier and G&A of $1.8 million versus $1.9 million, with net loss of $0.07 per share versus $0.15. Cash and equivalents were $11.7 million at September 30, 2026. Phase 2 start for rexaceract in Parkinson's expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 28, 2026 ·
Leadership Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, and she will also serve as principal financial and accounting officer. Her employment agreement sets a $275,000 base salary, a 35% target bonus, and an option for 130,000 shares. Form 8-K · SEC filing
Oct 1, 2026 ·
Clinical trial Presented poster at the Parkinson's congress in Seoul showing 12-month open-label extension data for rexaceract, with MDS-UPDRS Parts II and III scores stable over 360 days in 12 evaluable patients. Company plans to submit a new Phase 2 protocol to the FDA in coming weeks, with the trial starting Q1 2027. Form 8-K · SEC filing
Sep 28, 2026 ·
Leadership CFO Gianluca Fuggetta resigned, effective September 30, 2026, to pursue other opportunities. The board appointed CEO Gene Mack as interim principal financial officer effective October 1, 2026, while the company searches for a permanent replacement. Form 8-K · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 R&D expense of $2.1M, down from $2.8M, and G&A of $2.5M, up from $2.3M. Net loss was $0.11 per share versus $0.19 a year earlier. Cash was $13.1M as of June 30, 2026, down from $20.8M at year-end 2025. FDA cleared the IND for rexaceract, with Phase 2 expected to start in Q3 2026. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2028 · Phase 2 · Upcoming Trial · Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GANX holds $11.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.9M/quarter from operations,
an estimated runway of 9.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:77 · High
Cash runway 9 months +30
ATM program on file since Nov 2025 +15
Shelf registration (S-3, May 2025) +10
Going-concern doubt in the latest 10-Q +15Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.10-Q, Nov 2026
Share count 44,525,347 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GANX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GANX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.